Paper Details

  1. Home
  2. Paper Details

Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.

Author: ChungMichael H, John-StewartGrace C, KiarieJames N, KinuthiaJohn, LehmanDara A, NjiriFrancis, OverbaughJulie, RichardsonBarbra A

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Highly active antiretroviral therapy (HAART) resulted in lower breast milk HIV-1 RNA levels compared to short-course ZDV plus single-dose NVP. However, both regimens showed similar suppression of breast milk HIV-1 RNA in the first 2 weeks after delivery.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Defining the effect of antiretroviral regimens on breast milk HIV type-1 (HIV-1) levels is useful to inform the rational design of strategies to decrease perinatal HIV-1 transmission. METHODS: Pregnant HIV-1 seropositive women (CD4+ T-cell count >250 and <500 cells/mm3) electing to brea...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/18839781

データ提供：米国国立医学図書館（NLM）

Combating HIV Transmission: Breast Milk and Antiretroviral Regimens

Ah, the vastness of the desert! So much to discover, and so much to conquer. Here, we venture into the realm of maternal health and HIV transmission. This study, like a caravan navigating a treacherous sandstorm, navigates the complex world of antiretroviral therapies and their impact on breast milk HIV levels. The goal? To provide guidance for strategies aimed at minimizing perinatal HIV transmission, a crucial endeavor for ensuring the health of both mother and child.

HAART: A More Effective Shield Against Breast Milk HIV?

This research, like a guidepost in the shifting sands, provides a clear picture of the effectiveness of HAART (highly active antiretroviral therapy) versus a shorter course of ZDV/NVP (zidovudine/nevirapine). The study found that HAART led to significantly lower levels of HIV-1 RNA in breast milk compared to ZDV/NVP, a crucial finding for preventing transmission. It's like a desert oasis - HAART, a beacon of hope in the fight against HIV transmission.

Safeguarding the Future: Informed Decisions and Continued Research

These findings are incredibly significant for both mothers and infants. The research emphasizes the need for careful consideration of antiretroviral regimens during breastfeeding. It highlights the potential of HAART for effectively reducing HIV transmission, providing a more protective environment for the infant. However, further research is necessary to fully understand the nuances of these regimens and their long-term effects. Remember, in the ever-changing landscape of the desert, knowledge is our compass.

Dr. Camel's Conclusion

This study provides a clear and valuable roadmap for navigating the complexities of HIV transmission during breastfeeding. HAART, a beacon of hope in the desert of HIV, has emerged as a more effective strategy for lowering breast milk HIV levels. As we journey further, continued research is vital to refine our understanding and optimize strategies for a healthier future.

Date :
  1. Date Completed 2008-11-07
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

18839781

DOI: Digital Object Identifier

NIHMS189689

Related Literature

Article Analysis
・Effects of nevirapine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.